AlzeCure Pharma AB's NeuroRestore ACD856 has demonstrated anti-inflammatory and immunomodulating properties in preclinical studies, offering a promising avenue for disease modification in Alzheimer's disease. The findings will be presented at the Clinical Trials in Alzheimer's Disease (CTAD) conference in Madrid, Spain, from October 29 to November 1.
The abstract, titled 'Preclinical evidence for anti-inflammatory and immunomodulatory effects of NeuroRestore ACD856, a Trk-PAM in clinical development for the treatment of Alzheimer’s disease,' will be presented by Dr. Cristina Parrado-Fernández, Senior Scientist at AlzeCure, in collaboration with experts from Karolinska Institutet.
Preclinical Evidence
The presentation will highlight new preclinical results indicating that ACD856, the lead candidate in the NeuroRestore platform, exhibits both anti-inflammatory and immunomodulating effects. These effects were observed in aged animals and Alzheimer’s models, suggesting potential disease-modifying properties. Previous studies have shown that AlzeCure’s NeuroRestore candidates enhance communication between nerve cells and improve cognitive functions, such as learning and memory.
Therapeutic Potential
The unique pharmacological mechanism of NeuroRestore supports its use in multiple indications, including Alzheimer’s, Parkinson’s disease, and depression. ACD856 is currently being prepared for Phase II clinical studies in Alzheimer’s patients. Martin Jönsson, CEO of AlzeCure Pharma, emphasized the significance of these findings and the recognition from the CTAD conference, stating that the promising results further validate the potential of ACD856 as a disease-modifying treatment and underscore the company’s commitment to advancing research in neurodegenerative diseases.
The acceptance of this abstract at CTAD is seen as a validation of AlzeCure’s innovative approach and the NeuroRestore platform, positioning the company at the forefront of Alzheimer’s research.
